Medical Forum / Diseases and Disorders / Arthritis / July 2009
Literal Lube Job
|
|
Thread rating:  |
ironjustice - 30 Jul 2009 17:12 GMT Fat jabs cut cartilage destruction July 29 2009 at 09:06PM
Tiny globules of fat that are injected into painful joints could be a radical new treatment for osteoarthritis.
Thousands of the fat particles - each one no bigger than a speck of dust - are injected to protect the cartilage inside the joint from further damage.
Cartilage is the spongy material in the hips, knees, spine, wrists and shoulders that acts as the body's shock absorber, stopping the bones rubbing together.
But injury, illness or wear and tear can cause the cartilage to start breaking down.
As bones come into contact, the friction makes the joints swollen and painful.
The fat molecules, which are manufactured in a laboratory, are soft enough to help cushion the impact from everyday activities, but strong enough not to be destroyed under the strain of a working joint.
The treatment was developed in Israel by scientists at the Hebrew University of Jerusalem and the Technion Institute of Technology.
In tests, the scientists injected the fat particles into hip joints.
The results, published in the arthritis journal Wear, showed the fat jabs reduced the rate of cartilage destruction by 40 percent compared with 10 percent with an existing therapy, hyaluronic acid.
(Hyaluronic acid is sometimes injected into damaged joints to help keep cartilage lubricated and spongy.)
Professor Philip Conaghan, of the Arthritis Research Campaign, said a treatment that stopped cartilage breakdown was the "holy grail" for osteoarthritis.
But he said there was no guarantee this would actually reduce pain.
"One of the complexities is that we're not sure whether the pain comes from the bone underlying the cartilage or inflammation in the tissue lining the joints.
"So we should be careful about thinking that a treatment that reduces cartilage loss will necessarily improve pain. But we all hope it will." - Daily Mail
This article was originally published on page 15 of Cape Argus on July 29, 2009
--------------
Lack Of Critical Lubricant Causes Wear In Joints, First-Ever Study Finds Main Category: Arthritis News Article Date: 07 Nov 2007 - 1:00 PST
Mice that don't produce lubricin, a thin film of protein found in the cartilage of joints, showed early wear and higher friction in their joints, a new study led by Brown University researchers shows.
This link between increased friction and early wear in joints is a first; no other team of scientists has proven this association before. The finding, published in Arthritis & Rheumatism, sheds important light on how joints work. The discovery also suggests that lubricin, or a close cousin, could be injected directly into hips, knees or other joints inflamed from arthritis or injury -- a preventive treatment that could reduce the need for painful and costly joint replacement surgery.
In an editorial that accompanies the journal article, orthopedics researchers from Rush University Medical Center in Chicago call the research an "important contribution to the field" and note that the use of biomolecules like lubricin to prevent joint wear "could have a substantial clinical impact, if successful."
Gregory Jay, M.D, a Rhode Island Hospital emergency physician and an associate professor of emergency medicine and engineering at Brown, led the research. For 20 years, Jay has studied lubricin's role as a "boundary lubricant" by reducing friction between opposing layers of cartilage inside joints. In this new work, Jay and his colleagues set out to answer the next question: Does reducing friction actually prevent wear, or surface damage, in joints?
To find out, Jay and his team studied cartilage from the knees of mice that don't produce lubricin. Directly after birth, the cartilage was smooth. But in as little as two weeks, researchers found, the cartilage began to show signs of wear. Under an electron microscope, scientists could see that the collagen fibers that cartilage is composed of were breaking up, giving the surface a rough, frayed appearance. This damage is called wear, an early sign of joint disease or injury.
Jay and his team then took the work a step further. To better understand how lubricin works, they tried to see the structure of the film. So they put a tiny bit of the protein under an atomic force microscope. At the nanoscale, the molecule appeared as a mesh -- row upon row of interlocking fibers -- that could repel a microscope probe. This repulsion, created with water and electrical charges, shows how lubricin acts as a buffer, keeping opposing layers of cartilage apart.
"We demonstrated that lubricin reduces both friction and wear and also showed how, on a molecular level, it does this work in the body," Jay said. "What's exciting are the clinical implications. Arthritis and sports injuries damage the joints of thousands of people in the United States and millions of people worldwide each year. Our aim is to make a treatment that can actually prevent wear in the joints."
Through Rhode Island Hospital, Jay has filed two patents on the protein and its sequences and, in 2004, helped form Tribologics, a biotech company formed out of Rhode Island Hospital. The Massaschusetts-based business is developing an injection treatment for inflamed joints that contains lubricin.
Members of the research team included Jahn Torres, a former Brown graduate student in engineering; David Rhee, a former graduate student at Case Western Reserve University; Heikki Helminen, M.D., and Mika Hytinnen, M.D., from the University of Kuopio in Finland; Chung-Ja Cha, a research assistant at Rhode Island Hospital; Khaled Elsaid, a postdoctoral research fellow at Rhode Island Hospital; Kyung-Suk Kim, a professor of engineering at Brown; and Yajun Cui, M.D., and Matthew Warman, M.D., of Boston Children's Hospital and Harvard Medical School.
The National Institute of Arthritis and Musculoskelatal and Skin Diseases funded the work, along with the Academy of Finland, the McCutchen Foundation, the Howard Hughes Medical Institute and the Burroughs Wellcome Fund.
Source: Wendy Lawton Brown University
Who loves ya. Tom
Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
ken - 30 Jul 2009 21:15 GMT ironjustice - 31 Jul 2009 01:02 GMT Fat jabs cut cartilage destruction July 29 2009 at 09:06PM
Tiny globules of fat that are injected into painful joints could be a radical new treatment for osteoarthritis.
Thousands of the fat particles - each one no bigger than a speck of dust - are injected to protect the cartilage inside the joint from further damage.
Cartilage is the spongy material in the hips, knees, spine, wrists and shoulders that acts as the body's shock absorber, stopping the bones rubbing together.
But injury, illness or wear and tear can cause the cartilage to start breaking down.
As bones come into contact, the friction makes the joints swollen and painful.
The fat molecules, which are manufactured in a laboratory, are soft enough to help cushion the impact from everyday activities, but strong enough not to be destroyed under the strain of a working joint.
The treatment was developed in Israel by scientists at the Hebrew University of Jerusalem and the Technion Institute of Technology.
In tests, the scientists injected the fat particles into hip joints.
The results, published in the arthritis journal Wear, showed the fat jabs reduced the rate of cartilage destruction by 40 percent compared with 10 percent with an existing therapy, hyaluronic acid.
(Hyaluronic acid is sometimes injected into damaged joints to help keep cartilage lubricated and spongy.)
Professor Philip Conaghan, of the Arthritis Research Campaign, said a treatment that stopped cartilage breakdown was the "holy grail" for osteoarthritis.
But he said there was no guarantee this would actually reduce pain.
"One of the complexities is that we're not sure whether the pain comes from the bone underlying the cartilage or inflammation in the tissue lining the joints.
"So we should be careful about thinking that a treatment that reduces cartilage loss will necessarily improve pain. But we all hope it will." - Daily Mail
This article was originally published on page 15 of Cape Argus on July 29, 2009
--------------
Lack Of Critical Lubricant Causes Wear In Joints, First-Ever Study Finds Main Category: Arthritis News Article Date: 07 Nov 2007 - 1:00 PST
Mice that don't produce lubricin, a thin film of protein found in the cartilage of joints, showed early wear and higher friction in their joints, a new study led by Brown University researchers shows.
This link between increased friction and early wear in joints is a first; no other team of scientists has proven this association before. The finding, published in Arthritis & Rheumatism, sheds important light on how joints work. The discovery also suggests that lubricin, or a close cousin, could be injected directly into hips, knees or other joints inflamed from arthritis or injury -- a preventive treatment that could reduce the need for painful and costly joint replacement surgery.
In an editorial that accompanies the journal article, orthopedics researchers from Rush University Medical Center in Chicago call the research an "important contribution to the field" and note that the use of biomolecules like lubricin to prevent joint wear "could have a substantial clinical impact, if successful."
Gregory Jay, M.D, a Rhode Island Hospital emergency physician and an associate professor of emergency medicine and engineering at Brown, led the research. For 20 years, Jay has studied lubricin's role as a "boundary lubricant" by reducing friction between opposing layers of cartilage inside joints. In this new work, Jay and his colleagues set out to answer the next question: Does reducing friction actually prevent wear, or surface damage, in joints?
To find out, Jay and his team studied cartilage from the knees of mice that don't produce lubricin. Directly after birth, the cartilage was smooth. But in as little as two weeks, researchers found, the cartilage began to show signs of wear. Under an electron microscope, scientists could see that the collagen fibers that cartilage is composed of were breaking up, giving the surface a rough, frayed appearance. This damage is called wear, an early sign of joint disease or injury.
Jay and his team then took the work a step further. To better understand how lubricin works, they tried to see the structure of the film. So they put a tiny bit of the protein under an atomic force microscope. At the nanoscale, the molecule appeared as a mesh -- row upon row of interlocking fibers -- that could repel a microscope probe. This repulsion, created with water and electrical charges, shows how lubricin acts as a buffer, keeping opposing layers of cartilage apart.
"We demonstrated that lubricin reduces both friction and wear and also showed how, on a molecular level, it does this work in the body," Jay said. "What's exciting are the clinical implications. Arthritis and sports injuries damage the joints of thousands of people in the United States and millions of people worldwide each year. Our aim is to make a treatment that can actually prevent wear in the joints."
Through Rhode Island Hospital, Jay has filed two patents on the protein and its sequences and, in 2004, helped form Tribologics, a biotech company formed out of Rhode Island Hospital. The Massaschusetts-based business is developing an injection treatment for inflamed joints that contains lubricin.
Members of the research team included Jahn Torres, a former Brown graduate student in engineering; David Rhee, a former graduate student at Case Western Reserve University; Heikki Helminen, M.D., and Mika Hytinnen, M.D., from the University of Kuopio in Finland; Chung-Ja Cha, a research assistant at Rhode Island Hospital; Khaled Elsaid, a postdoctoral research fellow at Rhode Island Hospital; Kyung-Suk Kim, a professor of engineering at Brown; and Yajun Cui, M.D., and Matthew Warman, M.D., of Boston Children's Hospital and Harvard Medical School.
The National Institute of Arthritis and Musculoskelatal and Skin Diseases funded the work, along with the Academy of Finland, the McCutchen Foundation, the Howard Hughes Medical Institute and the Burroughs Wellcome Fund.
Source: Wendy Lawton Brown University
Who loves ya. Tom
Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
ironjustice - 31 Jul 2009 02:16 GMT Tiny globules of fat that are injected into painful joints could be a radical new treatment for osteoarthritis. <<
They wouldn't be injecting .. lecithin / phosphatidylcholine .. ? Just ramp up your vegetable oil intake .. ?
"Lecithin Vital Active Ingredient In Joints"
"8 different species of phosphatidylcholines were identified"
Boundary lubrication of joints: Characterization of surface-active phospholipids found on retrieved implants. Acta Orthop. 2007 Jun;78(3):309-14 Gale LR, Chen Y, Hills BA, Crawford R. Medical Engineering, Queensland University of Technology. Brisbane, QLD.
Background The identity of the vital active ingredient within synovial fluid (SF) - to which we owe the near frictionless performance of diarthrodial joints - has been the quest of researchers for many years. Initially, hyaluronic acid (HA) was thought to be the lubricant, but it has been shown not to possess the load-bearing ability required within the physiological joint. The glycoprotein fraction of synovial fluid (lubricin) has been shown to have the same lubricating ability as synovial fluid. All or part of this is thoughtto be due to the sur-face-active phospholipids (SAPLs) present in lubricin. We characterized the SAPLs adsorbed on the surface of retrieved prostheses which have been implicated as the boundary lubricant. Material and methods Rinsing fluids collected from the bearing surfaces of 40 prostheses removed from hip and knee revision operations were analyzed using highperformance liquid chromatography (HPLC). Results SAPLs were detected on all retrieved implants. During the study, 8 different species of phosphatidylcholines were identified. We also determined the relative concentration of each species, which suggested that the unsaturated SAPL species predominate. Interpretation It is of value to know the identity of the lubricating constituents of SF, not only for the future development of artificial joints, but also in developing cures for several disease processes in which lubrication plays a role.
PMID: 17611842
Who loves ya. Tom
Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
> Thousands of the fat particles - each one no bigger than a speck of > dust - are injected to protect the cartilage inside the joint from [quoted text clipped - 145 lines] > > DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk ken - 31 Jul 2009 02:51 GMT ironjustice - 31 Jul 2009 03:07 GMT Fat jabs cut cartilage destruction July 29 2009 at 09:06PM
Tiny globules of fat that are injected into painful joints could be a radical new treatment for osteoarthritis.
Thousands of the fat particles - each one no bigger than a speck of dust - are injected to protect the cartilage inside the joint from further damage.
Cartilage is the spongy material in the hips, knees, spine, wrists and shoulders that acts as the body's shock absorber, stopping the bones rubbing together.
But injury, illness or wear and tear can cause the cartilage to start breaking down.
As bones come into contact, the friction makes the joints swollen and painful.
The fat molecules, which are manufactured in a laboratory, are soft enough to help cushion the impact from everyday activities, but strong enough not to be destroyed under the strain of a working joint.
The treatment was developed in Israel by scientists at the Hebrew University of Jerusalem and the Technion Institute of Technology.
In tests, the scientists injected the fat particles into hip joints.
The results, published in the arthritis journal Wear, showed the fat jabs reduced the rate of cartilage destruction by 40 percent compared with 10 percent with an existing therapy, hyaluronic acid.
(Hyaluronic acid is sometimes injected into damaged joints to help keep cartilage lubricated and spongy.)
Professor Philip Conaghan, of the Arthritis Research Campaign, said a treatment that stopped cartilage breakdown was the "holy grail" for osteoarthritis.
But he said there was no guarantee this would actually reduce pain.
"One of the complexities is that we're not sure whether the pain comes from the bone underlying the cartilage or inflammation in the tissue lining the joints.
"So we should be careful about thinking that a treatment that reduces cartilage loss will necessarily improve pain. But we all hope it will." - Daily Mail
This article was originally published on page 15 of Cape Argus on July 29, 2009
--------------
Lack Of Critical Lubricant Causes Wear In Joints, First-Ever Study Finds Main Category: Arthritis News Article Date: 07 Nov 2007 - 1:00 PST
Mice that don't produce lubricin, a thin film of protein found in the cartilage of joints, showed early wear and higher friction in their joints, a new study led by Brown University researchers shows.
This link between increased friction and early wear in joints is a first; no other team of scientists has proven this association before. The finding, published in Arthritis & Rheumatism, sheds important light on how joints work. The discovery also suggests that lubricin, or a close cousin, could be injected directly into hips, knees or other joints inflamed from arthritis or injury -- a preventive treatment that could reduce the need for painful and costly joint replacement surgery.
In an editorial that accompanies the journal article, orthopedics researchers from Rush University Medical Center in Chicago call the research an "important contribution to the field" and note that the use of biomolecules like lubricin to prevent joint wear "could have a substantial clinical impact, if successful."
Gregory Jay, M.D, a Rhode Island Hospital emergency physician and an associate professor of emergency medicine and engineering at Brown, led the research. For 20 years, Jay has studied lubricin's role as a "boundary lubricant" by reducing friction between opposing layers of cartilage inside joints. In this new work, Jay and his colleagues set out to answer the next question: Does reducing friction actually prevent wear, or surface damage, in joints?
To find out, Jay and his team studied cartilage from the knees of mice that don't produce lubricin. Directly after birth, the cartilage was smooth. But in as little as two weeks, researchers found, the cartilage began to show signs of wear. Under an electron microscope, scientists could see that the collagen fibers that cartilage is composed of were breaking up, giving the surface a rough, frayed appearance. This damage is called wear, an early sign of joint disease or injury.
Jay and his team then took the work a step further. To better understand how lubricin works, they tried to see the structure of the film. So they put a tiny bit of the protein under an atomic force microscope. At the nanoscale, the molecule appeared as a mesh -- row upon row of interlocking fibers -- that could repel a microscope probe. This repulsion, created with water and electrical charges, shows how lubricin acts as a buffer, keeping opposing layers of cartilage apart.
"We demonstrated that lubricin reduces both friction and wear and also showed how, on a molecular level, it does this work in the body," Jay said. "What's exciting are the clinical implications. Arthritis and sports injuries damage the joints of thousands of people in the United States and millions of people worldwide each year. Our aim is to make a treatment that can actually prevent wear in the joints."
Through Rhode Island Hospital, Jay has filed two patents on the protein and its sequences and, in 2004, helped form Tribologics, a biotech company formed out of Rhode Island Hospital. The Massaschusetts-based business is developing an injection treatment for inflamed joints that contains lubricin.
Members of the research team included Jahn Torres, a former Brown graduate student in engineering; David Rhee, a former graduate student at Case Western Reserve University; Heikki Helminen, M.D., and Mika Hytinnen, M.D., from the University of Kuopio in Finland; Chung-Ja Cha, a research assistant at Rhode Island Hospital; Khaled Elsaid, a postdoctoral research fellow at Rhode Island Hospital; Kyung-Suk Kim, a professor of engineering at Brown; and Yajun Cui, M.D., and Matthew Warman, M.D., of Boston Children's Hospital and Harvard Medical School.
The National Institute of Arthritis and Musculoskelatal and Skin Diseases funded the work, along with the Academy of Finland, the McCutchen Foundation, the Howard Hughes Medical Institute and the Burroughs Wellcome Fund.
Source: Wendy Lawton Brown University
They wouldn't be injecting .. lecithin / phosphatidylcholine .. ? Just ramp up your vegetable oil intake .. ?
"Lecithin Vital Active Ingredient In Joints"
"8 different species of phosphatidylcholines were identified"
Boundary lubrication of joints: Characterization of surface-active phospholipids found on retrieved implants. Acta Orthop. 2007 Jun;78(3):309-14 Gale LR, Chen Y, Hills BA, Crawford R. Medical Engineering, Queensland University of Technology. Brisbane, QLD.
Background The identity of the vital active ingredient within synovial fluid (SF) - to which we owe the near frictionless performance of diarthrodial joints - has been the quest of researchers for many years. Initially, hyaluronic acid (HA) was thought to be the lubricant, but it has been shown not to possess the load-bearing ability required within the physiological joint. The glycoprotein fraction of synovial fluid (lubricin) has been shown to have the same lubricating ability as synovial fluid. All or part of this is thoughtto be due to the sur-face-active phospholipids (SAPLs) present in lubricin. We characterized the SAPLs adsorbed on the surface of retrieved prostheses which have been implicated as the boundary lubricant. Material and methods Rinsing fluids collected from the bearing surfaces of 40 prostheses removed from hip and knee revision operations were analyzed using highperformance liquid chromatography (HPLC). Results SAPLs were detected on all retrieved implants. During the study, 8 different species of phosphatidylcholines were identified. We also determined the relative concentration of each species, which suggested that the unsaturated SAPL species predominate. Interpretation It is of value to know the identity of the lubricating constituents of SF, not only for the future development of artificial joints, but also in developing cures for several disease processes in which lubrication plays a role.
PMID: 17611842
Who loves ya. Tom
Jesus Was A Vegetarian! http://tinyurl.com/2r2nkh
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
ken - 31 Jul 2009 03:17 GMT Happy Oyster - 31 Jul 2009 04:50 GMT > Tiny globules of fat Now this seems to be a oily joke the rusted cracked record did not realize...
 Signature **** WARNING **** The web-hoster Globat.com steals money from your credit card account. If you are a customer of Globat.com, never give them any credit card information. If you can't erase the information, then do delete the old card and get a new one! **** WARNING ****
|
|
|